Science
Opinion: Long COVID is solvable, but we need more clinical trials
We are living in an epidemic of chronic disease, with a growing number of pesticides, chemicals and food additives implicated in the declining health of Americans. Since 2019, another factor has been at play as well: The SARS-CoV-2 virus has driven a huge increase in chronic health consequences, broadly referred to as long COVID.
Infection by the COVID-19 virus is a consequential new variable in our nation’s health that can substantially increase the incidence of serious conditions such as neurological disease, heart attack and stroke. Approximately 6% of U.S. adults suffer from long COVID — at a cost to our economy estimated at $3.7 trillion a year.
Contrary to what is often portrayed in the media, long COVID is not a mystery. There is a straightforward reason at least some people may remain ill “after COVID”: They still have the SARS-CoV-2 virus — or parts of the virus — in their bodies. For example, one team found that almost two years after infection, long COVID patients had not yet cleared the virus from their gut tissue. These persistent viral reservoirs appear to leak spike protein — the part of the virus that gives coronaviruses their distinctive “crown” appearance — into blood circulation, potentially driving inflammation of the brain and other organs, and increasing health consequences such as heart disease.
While early efforts are underway to help clear persistent viral reservoirs, more well-designed clinical trials are desperately needed to help the millions suffering from long COVID return to normal life. To address this emergency, we formed a global consortium of scientists to accelerate research, including by publishing a recent roadmap for testing medications aimed at clearing persistent SARS-CoV-2. Our proposal draws on successful approaches from cancer research and treatment strategies used against other viral infections such as HIV and hepatitis C; these histories offer lessons about trial design, drug candidates and how to develop tests for persistent viral reservoirs.
The most promising trials may also be among the most complex to carry out, because they may combine medications targeting the virus — such as antiviral drugs and monoclonal antibodies — with treatments to activate immune cells. It may also be important to simultaneously address other problems associated with long COVID, such as immune dysfunction and microbiome changes.
To add another variable to these complex trials we do not yet know the duration of treatment each type of medication might need. For example, current long COVID clinical trials are testing 5 to 15 days of antivirals like Paxlovid. But treatment of persistent hepatitis C virus requires 8 to 12 weeks of antiviral therapy. In cats with feline infectious peritonitis — also caused by a persistent coronavirus — 12 weeks of antiviral treatment is required for effective treatment. Such an extended approach may require careful studies to test the safety of potential long COVID medications when given for longer periods of time.
All of this will be an interdisciplinary global undertaking. But the effort is worth it.
The looming question now is: Who will pay for drug development and trials? Big pharmaceutical companies can afford to run trials, and they should. But small biotech companies do not have the same resources. Already, because of this limitation, multiple antivirals and monoclonal antibodies with the potential to help long COVID patients are sitting on shelves rather than being studied in patients who urgently need more options.
Government and private funding should solve that by helping smaller companies run early-stage trials. These programs, which must be agile and adaptive and continually incorporate the real-world experience of patients into their design, are ideal for “high-risk, high-reward” agencies like the Advanced Research Projects Agency for Health, which is part of Health and Human Services. It was therefore encouraging to hear Robert F. Kennedy Jr., who is now the secretary of Health and Human Services, say during his recent confirmation hearing that he would enthusiastically work with Congress to direct long COVID funding toward much-need clinical trials.
If public funding supports the development of any new long COVID drug, the data and resulting therapies should be open source and available to manufacturers of generics, which will increase trust in the treatments and will benefit patients across the globe.
The world has been in this position before, when facing HIV in the late 1980s and early 1990s. A combination of rapid government and private funding made multiple companies more willing to engage in drug development. There are now more than 25 approved drugs for HIV infection. The development of these treatments transformed HIV from a life-threatening infection to a manageable chronic condition — for those with access to the medications. In some cases, public support compelled otherwise-competing drug companies to work together for a greater good.
Lessons learned from fighting SARS-CoV-2 could also help scientists in the battles against other conditions, because long COVID is just one of many chronic disease states that start with an infection. Others include chronic or post-treatment Lyme disease, myalgic encephalomyelitis and post-dengue fatigue syndrome. Persistent viral infection is also increasingly being documented among Alzheimer’s and multiple sclerosis patients.
The urgency of long COVID is a call to arms for government and private funders to help bring medications and protocols to the people who need them. Ultimately, far more may benefit from the knowledge gained.
Amy D. Proal, a microbiologist, is a founder of the PolyBio Research Foundation, a nonprofit that supports research into the root cause drivers of chronic disease.
Science
Pace of N.I.H. Funding Slows Further in Trump’s Second Year
Spending on new medical research by the National Institutes of Health has fallen roughly $1 billion behind the pace of years past, delaying thousands of scientific projects and raising concerns within the agency that it may struggle to pay out the money it was allotted by Congress.
Instead of canceling grants en masse, as the N.I.H. did in the first year of this Trump presidency, it is now vetting them before approval with a “computational text analysis tool” that scans for terms including “racism,” “gender” and “vaccination refusal,” according to documents obtained by The New York Times.
That tool was meant to formalize a campaign against “woke science” that was initiated last year by the Elon Musk-led Department of Government Efficiency.
But the screening system is now exacerbating a slowdown in research spending: The N.I.H. awarded only about 1,900 new and competitive grants from October to late March, less than half the number it tended to give out by that point in the fiscal year during the Biden administration, an analysis by The Times showed.
The heaviest damage to the grantmaking apparatus was done by the protracted government shutdown in the fall, which delayed grant review meetings by months. The N.I.H. has struggled to catch up, and delays are affecting fields far beyond those ostensibly targeted by the administration’s crusade against diversity, equity and inclusion.
As of late March, for example, the National Cancer Institute had earmarked only about $72 million for new and competitive research grants, less than one-third of the nearly $250 million it had agreed to spend by that point in a typical fiscal year during the Biden administration, according to The Times’s analysis.
“It means that people get fired because there is uncertainty about whether the grant will come through,” said Dr. Joshua Gordon, a professor of psychiatry at Columbia University and a former director of the National Institute of Mental Health. “It means budgets get busted. It means research projects get stalled.”
However alarming the canceled grants and spending delays were last year, Dr. Gordon said, “I’m more worried this year.”
The Department of Health and Human Services, which oversees the N.I.H. and is led by Secretary Robert F. Kennedy Jr., has become involved this year in flagging certain grant awards and stopping their release, according to emails reviewed by The Times.
Mr. Kennedy faced sharp criticism from Democratic and Republican lawmakers alike over N.I.H. spending delays in congressional hearings this week. He is set to appear at two more hearings on Wednesday.
The N.I.H. has fallen behind in part because it lost thousands of workers last year to layoffs and early retirements. In some branches of the agency, what workers remain can barely keep up with renewing existing grants, much less awarding new ones.
One N.I.H. institute has less than half of the workers needed to vet grants for legal and financial compliance, employees were told at a recent meeting, notes from which were reviewed by The Times.
Under the most dire projections, the institute could leave $500 million of congressionally appropriated funding on the table because of difficulties processing grants, N.I.H. officials said at that meeting. They were temporarily deploying career scientists to what were effectively business roles to speed up grant awards.
The N.I.H. director, Dr. Jay Bhattacharya, has said that he is trying to root out ideologically motivated and insufficiently rigorous science. Conservatives accuse the N.I.H. of having fostered such research during the Obama and Biden presidencies by, for example, encouraging grant proposals on sexual- and gender-minority groups.
“Scientists will no longer have to mouth D.E.I. shibboleths to garner funding,” Dr. Bhattacharya and his top deputy wrote in an online article in December, the day before the N.I.H. outlined the new screening process to its employees.
Andrew Nixon, a health department spokesman, blamed the spending shortfall on “the Democrat-led shutdown,” which he said “delayed N.I.H.’s ability to issue grants” at the start of the fiscal year. Since then, he said, “timelines have returned to typical funding patterns.”
He added that the agency “uses a variety of review tools to ensure alignment with agency priorities” and that it was working to hire additional employees. “The N.I.H. intends to obligate all appropriated funds, as directed by Congress,” he said.
To understand why spending has slowed so dramatically at the N.I.H., the world’s premier funder of medical research, The Times interviewed 10 agency employees and reviewed internal documents, including spreadsheets of grants flagged by the screening tool and the list of roughly 235 terms it searches for.
The employees spoke on the condition of anonymity because they were not authorized to comment publicly.
The documents painted a picture of an agency whose leaders were seeking to exert greater control over scientific spending by, among other things, deciding whether certain grants were compatible with agency priorities. But in clamping down on the funding process, the N.I.H. created new choke points, leaving some proposals in limbo for days or weeks.
That has frustrated some senior N.I.H. officials, one of whom lamented in an email seen by The Times that it was taking too long to rework grant proposals. The official asked his staff to simply strip the proposals of disfavored terms instead.
The delays have also angered lawmakers. Congress sets the country’s medical research spending levels, even as the administration has leeway to prioritize types of studies. And despite Mr. Trump’s proposing major cuts last year, Congress preserved the N.I.H. budget at roughly $47 billion for 2026.
“It is very frustrating to understand that this administration can circumvent dollars that were designated for our scientists,” said Senator Angela Alsobrooks, Democrat of Maryland.
Congress’s budget buoyed American scientists. By late 2025, many believed that they had weathered the worst of Trump-era funding problems. The N.I.H. spent aggressively toward the end of the last fiscal year, overcoming earlier blockages and delays.
The Supreme Court also let stand a lower court’s ruling that the policy behind the cancellation of more than $780 million in N.I.H. grants was probably unlawful, a victory for groups that had argued the terminations were arbitrary and capricious.
But the Trump administration was preparing a far more systematic crackdown on what it saw as unreliable research.
In August, Dr. Bhattacharya publicly outlined the agency’s new priorities, including opposition to “research based on ideologies that promote differential treatment of people based on race or ethnicity,” a template that could be used to guide grant reviews.
Then, in December, the N.I.H. introduced its employees to the “computational text analysis tool,” allowing the agency to comb through new grant proposals and existing projects for phrases suggesting a grant “may not align with N.I.H. priorities,” a guidance document would later tell employees.
Roger Severino, a vice president of the conservative Heritage Foundation and a health official in the first Trump administration, said that weeding out such grants was necessary to rid the N.I.H. of the “politicization” of the Obama and Biden eras.
If the result was less spending on science, he said, that was only because the agency had been wasting money.
“There was a tremendous amount of bloat that grew up like barnacles on the N.I.H. research ship,” Mr. Severino said. “Those barnacles are being scraped off.”
Within some divisions of the N.I.H., the text search tool is flagging as many as half of grants, officials said, requiring staff scientists to extensively document how they will be reworked or why they already conform to agency priorities.
Flagged grants address cancer, diabetes, autoimmune diseases, H.I.V., heart disease, stroke, Alzheimer’s disease, nutrition and prenatal care, internal documents show.
In part because many of them look at the use of screenings or treatments, they sometimes include mention of “inequities” in access to care or “minority” groups who disproportionately suffer from a disease, causing the system to deem the grants not “clean.”
In one case, a biological science grant was held up for a week because the proposal had used “sex” interchangeably with “gender,” a flagged word.
American scientists already spend some 40 percent of their time on grant-related administrative tasks. Now they are being deluged by ever more paperwork, said Dr. Michael Lauer, who led external grantmaking at the N.I.H. until last year.
And because the N.I.H. is awarding grants to far fewer researchers this year, the chances of success have rarely been lower.
“This is lost time for all of us,” Dr. Lauer said. “Instead of spending their time doing science and hopefully making discoveries that will make us all healthier, they’re rewriting grant applications.”
Sheryl Gay Stolberg contributed reporting.
Methodology
The Times analyzed N.I.H. grants data from N.I.H. RePORTER for the fiscal years 2021 through 2026. The analysis excludes awards for intramural research conducted at the N.I.H. Clinical Center. The analysis focuses on new awards (Type 1 awards) and competitive renewals (Types 2, 4 and 9).
The analysis uses data through March 2026, the most recent month comparable to prior years. Previous records suggest that the data available on RePORTER for that month, however, may still be missing up to 10 percent of awards. The analysis accounts for that possibility.
Science
Lyrids Meteor Shower: How to Watch, Peak Time and Weather Forecast
Our universe might be chock-full of cosmic wonder, but you can observe only a fraction of astronomical phenomena with the naked eye. Meteor showers, natural fireworks that streak brightly across the night sky, are one of them.
The latest observable meteor shower will be the Lyrids, which has been active since April 14 and is forecast to continue through April 30. The shower reaches its peak April 21 to 22, or Tuesday night into Wednesday morning.
According to NASA, the Lyrids are one of the oldest known meteor showers, and have been enjoyed by stargazers for nearly 3,000 years. Their bright, speedy streaks are caused by the dusty debris from a comet named Thatcher. They appear to spring from the constellation Lyra, which right now can be seen in the eastern sky at night in the Northern Hemisphere.
The moon will be about 27 percent full tonight, appearing as a thick crescent in the sky, according to the American Meteor Society.
To get a hint at when to best watch for the Lyrids, you can use this tool, which relies on data from the Global Meteor Network. It shows fireball activity levels in real time.
And while you gaze at the heavens, keep an eye out for other stray meteors streaking across the night sky. Skywatchers are reporting that the amount of fireballs is double what is usually seen by this point in the year.
Where meteor showers come from
There is a chance you might see a meteor on any given night, but you are most likely to catch one during a shower. Meteor showers are caused by Earth passing through the rubble trailing a comet or asteroid as it swings around the sun. This debris, which can be as small as a grain of sand, leaves behind a glowing stream of light as it burns up in Earth’s atmosphere.
Meteor showers occur around the same time every year and can last for days or weeks. But there is only a small window when each shower is at its peak, which happens when Earth reaches the densest part of the cosmic debris. The peak is the best time to look for a shower. From our point of view on Earth, the meteors will appear to come from the same point in the sky.
The Perseid meteor shower, for example, peaks in mid-August from the constellation Perseus. The Geminids, which occur every December, radiate from the constellation Gemini.
How to watch a meteor shower
Michelle Nichols, the director of public observing at the Adler Planetarium in Chicago, recommends forgoing the use of telescopes or binoculars while watching a meteor shower.
“You just need your eyes and, ideally, a dark sky,” she said.
That’s because meteors can shoot across large swaths of the sky, so observing equipment can limit your field of view.
Some showers are strong enough to produce up to 100 streaks an hour, according to the American Meteor Society, though you probably won’t see that many.
“Almost everybody is under a light-polluted sky,” Ms. Nichols said. “You may think you’re under a dark sky, but in reality, even in a small town, you can have bright lights nearby.”
Planetariums, local astronomy clubs or even maps like this one can help you figure out where to go to escape excessive light. The best conditions for catching a meteor shower are a clear sky with no moon or cloud cover, sometime between midnight and sunrise. (Moonlight affects visibility in the same way as light pollution, washing out fainter sources of light in the sky.) Make sure to give your eyes at least 30 minutes to adjust to seeing in the dark.
Ms. Nichols also recommends wearing layers, even during the summer. “You’re going to be sitting there for quite a while, watching,” she said. “It’s going to get chilly, even in August.”
Bring a cup of cocoa or tea for even more warmth. Then lie back, scan the sky and enjoy the show.
Where weather is least likely to affect your view
Storm systems sweep across the country in early spring, and some will be obscuring skies tonight. But there will still be plenty of areas with clear skies, particularly in parts of the central United States.
“The best spot is going to be in the Upper Midwest,” said Rich Bann, a meteorologist with the Weather Prediction Center.
Minnesota, Wisconsin and Iowa will offer especially good sky-viewing weather and a beach on the Great Lakes could be a nice spot to look up at the stars.
But don’t expect to view the show from Chicago, as Illinois could see some thunderstorms. The weather will be better in the Northern and Central Plains, particularly the eastern Dakotas.
High, wispy clouds are expected over the Ohio and Tennessee Valleys and into parts of the Mid-Atlantic. But, Mr. Bann said, “you may be able to see some shooting stars through thin clouds.”
Clouds will be draped across much of the Southeast and the Northeast, though there could be some clearing in Florida, Georgia, the Carolinas and Virginia. Remember, the meteors could be visible all night long. If you look outside and see clouds, try again later.
Catching the spectacle will be challenging across much of the West, particularly from Washington into Northern California, where a storm system is bringing rain and snow. That system will move east overnight.
There are likely to be some pockets of clear skies at times across southern Nevada, northwest Arizona and southwest Utah, Mr. Bann said.
Amy Graff contributed reporting.
Science
FBI probes cases of missing or dead scientists, including four from the L.A. area
WASHINGTON — Amid growing national security concerns, the FBI said Tuesday that it has launched a broad investigation in the deaths or disappearances of at least 10 scientists and staff connected to highly sensitive research, including four from the Los Angeles area.
“The FBI is spearheading the effort to look for connections into the missing and deceased scientists. We are working with the Department of Energy, Department of War, and with our state and state and local law enforcement partners to find answers,” the agency said in a statement.
The FBI’s announcement comes after the House Oversight Committee announced that it would investigate reports of the disappearance and deaths of the scientists, sending letters seeking information from the agencies involved in the federal inquiry as well as NASA, which owns the Jet Propulsion Laboratory in La Cañada Flintridge, where three of the missing or dead scientists worked.
“If the reports are accurate, these deaths and disappearances may represent a grave threat to U.S. national security and to U.S. personnel with access to scientific secrets,” Reps. James Comer (R-Ky.), chairman of the committee, and Eric Burlison (R-Mo.) wrote in the letters.
President Trump told reporters last week that he had been briefed on the missing and dead scientists, which he described as “pretty serious stuff.” He said at the time that he expected answers on whether the deaths were connected “in the next week and a half.”
Michael David Hicks, who studied comets and asteroids at JPL, was the first of the scientists who disappeared or died. He died on July 30, 2023, at the age of 59. No cause of death was disclosed.
A year later, JPL physicist Frank Maiwald died at 61, with no cause of death disclosed.
Two other Los Angeles scientists are part of the string of deaths and disappearances.
On June 22, 2025, Monica Jacinto Reza, a materials scientist at JPL, disappeared while on a hike near Mt. Waterman in the San Gabriel Mountains.
On Feb. 16, Caltech astrophysicist Carl Grillmair was fatally shot on the porch of his Llano home. The Los Angeles County Sheriff’s department arrested Freddy Snyder, 29, in connection with the shooting. Snyder had been arrested in December on suspicion of trespassing on Grillmair’s property.
Snyder has been charged with murder.
There is no evidence at this point that the deaths and disappearances, which occurred over a span of four years, are connected.
A spokesperson for NASA, which owns JPL, said in a statement on X that the agency is “coordinating and cooperating with the relevant agencies in relation to the missing scientists.
“At this time, nothing related to NASA indicates a national security threat,” agency spokesperson Bethany Stevens wrote. “The agency is committed to transparency and will provide more information as able.”
Representatives from Caltech, which manages JPL, did not immediately respond to a request for comment.
-
News6 minutes agoCalifornia Candidates to Appear in First Major Debate After Swalwell
-
Politics12 minutes agoVideo: Virginia Voters Approve New Map Favoring Democrats
-
Business18 minutes agoOil Prices Rise as Investors Weigh Cease-Fire Extension
-
Science24 minutes agoPace of N.I.H. Funding Slows Further in Trump’s Second Year
-
Health30 minutes agoAging in Place: How Technology Might Help You Grow Old at Home
-
Culture42 minutes agoBook Review: ‘Israel: What Went Wrong?,’ by Omer Bartov
-
Lifestyle48 minutes agoStreet Style Look of the Week: Airy Beachy Clothes
-
Education54 minutes agoÉcole des Sables, Africa’s Premier Dance School, Faces a Precarious Future